Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

Gilead Sciences Inc. closed 9.09% short of its 52-week high of $119.96, which the company achieved on March 10th.

Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

Gilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for our updates on GILD and MRK.

The scheme involved incentives to healthcare providers, leading to false claims to government programs like Medicaid.

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...

CHICAGO Attorney General Kwame Raoul, as part of a bipartisan coalition of 49 attorneys general, announced a $202 million multistate settlement agreement ...

Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...

LOS ANGELES, July 16, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that ...